Hao Ding biotech anti-cancer new drug OBI-3424 obtains FDA-issued orphan drug qualification

HCC is the sixth-largest cancer in the world, but it is rare in the United States, with about 61,483 cases in 2018HCC is a deadly cancer with a five-year survival rate of 12.2%, the third leading cause of cancerwhile most HCC is preventable, the incidence in the United States has been rising in recent yearsThe cause may be related to the prevalence of common risk factors such as chronic liver disease, viral hepatitis and cirrhosisBecause HCC patients are prone to resistance to standard treatments, they urgently need effective alternative therapies to alleviate the diseaserecently, TAIWAN," said OBI Pharma, A., taiwan, announced that thecompany(actively developing a new drug for anticancer(the U.SFDA(the u.Sfda is qualified for the treatment of hepatocellular carcinoma (HCC)about the OBI-3424OBI-3424 is a first-in-class DNA alkane treatmentdrug() targeting the expression of altrexone reductase 1C3 (AKR1C3)the OBI-3424, developed by HaoDing, is a new small molecule pre-drug of first-in-class, which selectively targets cancers that over-express AKR1C3 and, in the presence of AKR1C3 enzymes, selectively releases powerful DNA alkanesThis selective activation model distinguishes THE OBI-3424 from traditional alkanes such as cyclophosphamide and isocyclphosphamide .ifosfamideAKR1C3 overexpression is present in a variety of therapeutic lyser resistant and refractory cancers, including HCC, desperation-resistant prostate cancer (CRPC) and T-cell acute lympholeukemia leukemia (T-ALL)AKR1C3 is highly expressive in up to 15 solid tumors and blood tumorsCurrently, phase 1/2 of the studies conducted in patients with solid tumors, including HCC and CRPC, have begun to be enrolled at the University of Texas MD Anderson Cancer Center